Previous work revealed that distinct pathostates require state-specific neuromodulation to have a disease-modifying effect in Parkinson’s disease (PD). During the second funding period project A01 aims to identify state-specific bio- and physio-markers, identify the compensatory mechanisms which prevent motor dysfunction despite neurodegeneration in early disease states, and develop state-specific neurostimulation which enhances these compensatory mechanisms. Together this work will enable stratification of PD patients by pathostates and implementation of state-specific neurostimulation to halt PD progression in all disease states.